Lv6
1770 积分 2022-05-25 加入
Natural history and phenotype-genotype correlations in GJB2-related hearing loss: a systematic and comprehensive review
15天前
已完结
Spatial, temporal, and molecular heterogeneity of ADC targets in high-grade serous ovarian carcinoma
16天前
已完结
Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study
17天前
已关闭
NOTCH1 Mutations Are Associated with Therapy-Resistance in Patients with B-Cell Lymphoma Treated with CD20xCD3 Bispecific Antibodies
17天前
已关闭
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
17天前
已完结
SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)
17天前
已关闭
Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study
17天前
已关闭
Trop2, Nectin-4, and PD-L1 expression profiles in esophageal squamous cell carcinoma: Implications for combined immunotherapy and ADC targeted therapies
23天前
已完结
Deficiency of tumor-expressed B7-H3 augments anti-tumor efficacy of anti-PD-L1 monotherapy rather than the combined chemoimmunotherapy in ovarian cancer
23天前
已完结
皖公网安备34019202002308
